April 22, 2016

April 22, 2016

The 10 most diverse hospitals and health systems
Becker’s Hospital Review – April 21
Here are the DiversityInc Top 10 Hospitals and Health Systems in 2016:
No. 1 — Henry Ford Health System (Detroit)
No. 2 — Cleveland Clinic
No. 3 — Mount Sinai Health System (New York City)
No. 4 — Northwell Health (Great Neck, N.Y.)
No. 5 — Mayo Clinic (Rochester, Minn.)
No. 6 — Moffitt Cancer Center (Tampa, Fla.)
No. 7 — TriHealth (Cincinnati, Ohio)
No. 8 — Massachusetts General Hospital (Boston)
No. 9 — Advocate Health Care (Chicago)
No. 10 — Bon Secours Health System (Marriottsville, Md.)

Miles for Moffitt funds cancer research
WTSP – April 21
Money raised from the event funds research at Moffitt Cancer Center. Researcher Anna Giuliano is working to prevent mouth cancers in men and has benefited from race money.

VICC’s Annual Scientific Retreat set for May 6
Vanderbilt Reporter – April 21
Guest speakers include Lewis Cantley, Ph.D., Weill Cornell Medical College, Chi Van Dang, M.D., Ph.D., Abramson Cancer Center, University of Pennsylvania, Robert Gillies, Ph.D., Moffitt Cancer Center, and Craig Thompson, M.D., Memorial Sloan Kettering Cancer Center.

Plastic surgery is – and isn't – what many think
Vero News – April 21
A University of South Florida graduate who also served a two-year oncology fellowship at Tampa's Moffitt Cancer Center, Durkin freely admits that the bulk of his practice could certainly be called “cosmetic” though he quickly adds, “We're also doing a lot of melanoma care; a lot of support for dermatologists in the community.”

Histone Deacetylase Inhibitors Shown to Restimulate T Cells, Improve Immunotherapy in Lung Cancer
Oncology  Nurse Advisor – April 20
"These results suggest that combination of HDAC inhibitors with PD-1 blockade represents a promising strategy for lung cancer treatment," said Amer Beg, PhD, professor in the Immunology Program at University of South Florida H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, and lead author of the study.

Drug Promising Against Rare Skin  Cancer
HealthDay.com – April 19
“For these patients, the response to chemotherapy typically lasts two to four months at best,” said Dr. Nikhil Khushalani, of the Moffitt Cancer Center in Tampa, Fla. “And metastatic MCC is invariably fatal.”

Histone Deacetylase Inhibitors Shown to Restimulate T Cells, Improve Immunotherapy in Lung Cancer
Oncology Nurse Advisor – April 19
The H. Lee Moffitt Cancer Center and Research Institute has started a clinical trial to test the combination of an HDAC inhibitor and PD-1 inhibitor for stage IV non-small cell lung cancer. The trial is currently recruiting participants.

Annual boatyard bash raises funds for CMA and Moffitt
Tampa Bay Newspapers – April 18
Proceeds from the event will benefit the Clearwater Marine Aquarium and Moffitt Cancer Center.

Considering Maintenance Therapy in mCRC
OncLive – April 18
Richard Kim, MD: I follow the CAIRO-3 data you mentioned. I use capecitabine and bevacizumab. There are a lot of data out there after my study, but out of those, the CAIRO-3 has probably some of the more robust data.

TG Therapeutics (TGTX) Announces Presentation of Preclinical TGR-1202 Data; Dose Dependent Cytotoxicity Noted
Street Insider – April 18
As part of an ongoing research collaboration with the H. Lee Moffitt Cancer Center and Research Institute in Tampa, FL, data was generated comparing TGR-1202 with the PI3K-delta inhibitors idelalisib and duvelisib in in-vitro models assessing the impact on T-cell subsets.

Rare Sarcomas Pose Significant Hurdles, But Foster Collaboration
OncLive – April 18
“I hope that we can really lead the field of oncology in how we handle rare cancers,” says Reed, director of the Adolescent and Young Adult Program and medical director of the Department of Sarcoma at Moffitt Cancer Center.

Dr. Anthony Porter Features Full Service Dermatology, Aesthetic Medicine In Brevard
Space Coast Daily – April 18
“There are certain conditions, such as psoriasis and cutaneous t-cell lymphomas, for which it is very effective and safe. It is so good that we get referrals for it from Moffitt Cancer Center.

Protective Mastectomies that Preserve Nipple Safe for Women at High Breast Cancer Risk
Health Canal – April 17
The study’s senior author is Shawna Willey, M.D., of Georgetown University. The co-authors are Richard Gray, M.D., and Sarah McLaughlin, M.D., of Mayo Clinic; Anne Peled, M.D., of the University of California San Francisco; Rachel Greenup, M.D., of Duke University; John Kiluk, M.D., of Moffitt Cancer Center; Virgilio Sacchini, M.D., of Memorial Sloan Kettering; and Julia Tchou, M.D., Ph.D., of the University of Pennsylvania.

Anti–PD-1 immunotherapy confers ‘encouraging’ survival benefit in metastatic melanoma
Healio – April 17
Joseph Markowitz, MD, PhD, a medical oncologist in the department of cutaneous oncology at Moffitt Cancer Center, offers insights into a study presented at AACR Annual Meeting that showed more than one-third of patients with advanced melanoma treated with the anti–PD-1 antibody nivolumab (Opdivo, Bristol Myers Squibb) survived 5 years.

Moffitt Cancer Center to Host Charity Swim May 21
Tampa Patch – April 17
For the fifth straight year, Swim Across America will hit the beach to help Moffitt Cancer Center search for a cure for metastatic melanoma and childhood cancers.


Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.